Yahoo  Aug 17  Comment 
Merck (MRK) and Japanese partner Eisai gains an FDA approval for Lenvima label expansion. The anti-cancer drug receives the regulatory body's nod for the first line treatment of unresectable HCC.
FiercePharma  Aug 17  Comment 
Eisai and Merck’s fast-growing Lenvima has got a brand-new market—and Bayer’s Nexavar now has some company in the previously untreated liver cancer arena.
FiercePharma  Aug 3  Comment 
Merck & Co. likely expected big numbers from Eisai’s Lenvima when it agreed in March to fork over $5.8 billion to share rights to the drug. And those numbers are rolling in.
SeekingAlpha  Aug 1  Comment 

You may also be interested in articles related to Eisai Co. Ltd. (ESALY):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki